Crinetics Launches CAH Trial: Don’t Miss This Opportunity!

Introduction

Crinetics Pharmaceuticals recently dosed the first patient in a pivotal trial for congenital adrenal hyperplasia (CAH) (za.investing.com). But CAH is also the ticker symbol for Cardinal Health, Inc. – a longstanding healthcare distribution giant. While the biotech’s CAH trial grabs headlines, the real opportunity for investors might lie with Cardinal Health (NYSE: CAH). Cardinal Health has quietly transformed over the past few years, leveraging its stable core business and shareholder-friendly policies. This report dives into Cardinal’s dividend profile, leverage, valuation, and risks to assess whether investors should pay attention to this overlooked titan.

Company Overview

Cardinal Health is one of America’s “Big Three” pharmaceutical distributors, alongside McKesson and AmerisourceBergen. It operates two segments: a Pharmaceutical segment (drug distribution and related services) and a Medical segment (medical and laboratory products). The Pharmaceutical segment generates about 91% of revenue (~$165 billion annually) while Medical contributes ~9% (www.cnbc.com). This makes Cardinal the smallest of the top three distributors, which together control ~90% of the U.S. drug wholesale market (www.cnbc.com). In fiscal 2024, Cardinal’s total revenue reached a record $226.8 billion (newsroom.cardinalhealth.com) – a testament to its scale in the healthcare supply chain.

Historically, Cardinal’s margins are thin (as is typical in distribution), but volume and efficiency are key. Recent leadership changes and an activist-driven strategic review have sharpened its focus. In 2022, activist investor Elliott Management secured board seats and helped establish a Business Review Committee to evaluate Cardinal’s portfolio and operations (www.prnewswire.com). Under new CEO Jason Hollar, the company enacted a Medical segment improvement plan and optimized its strategy (newsroom.cardinalhealth.com). By FY2024, these efforts showed tangible results: the Medical products segment swung back to profitability and overall earnings hit all-time highs (newsroom.cardinalhealth.com). Cardinal Health today is a mission-critical but rejuvenated player in global healthcare logistics.

Dividend Policy and Shareholder Returns

Cardinal Health has a long track record of returning cash to shareholders. The company has raised its dividend for 29 consecutive years (www.dividend.com), placing it among the elite Dividend Aristocrats. However, recent increases have been modest – on the order of ~1% per year. For example, the FY2023 dividend totaled $1.98 per share, just 1% higher than FY2022 (www.sec.gov). The current quarterly payout is $0.5107, equating to $2.04 annually (ir.cardinalhealth.com). Due to a surging stock price, the dividend yield has compressed to roughly 0.98% forward – relatively low by historical standards (www.dividend.com). This yield, while safe, is less attractive for pure income investors (Dividend.com gives Cardinal’s yield a “D” rating) (www.dividend.com).

That said, dividend safety is superb. In FY2024 Cardinal generated $3.9 billion in adjusted free cash flow, an all-time high (newsroom.cardinalhealth.com). The cash dividend consumed only about $525 million (www.sec.gov), a payout ratio under 15% of free cash flow. Ample cash coverage means the dividend is well-protected and could continue its slow-growth trajectory. Importantly, Cardinal has augmented the modest dividend with aggressive share buybacks. Following Elliott’s involvement, buybacks spiked – the company repurchased $2.0 billion of its own stock in FY2023 (www.sec.gov) (quadruple the buybacks of two years prior). This shrank the diluted share count from 294 million in 2021 to ~262 million in 2023 (www.sec.gov), giving a nice boost to earnings per share. In total, Cardinal returned over $2.5 billion to shareholders in FY2023 via dividends and buybacks (newsroom.cardinalhealth.com), and continued repurchases in FY2024 as well (newsroom.cardinalhealth.com). The bottom line is a shareholder-friendly capital return policy: a reliable (if slow-growing) dividend and value-accretive buybacks funded by strong cash flows.

Leverage, Debt Maturities, and Coverage

Cardinal Health’s balance sheet is solid after years of cash generation and recent portfolio pruning. As of June 30, 2023, the company carried $4.7 billion in total long-term obligations (including current debt) (www.sec.gov). Against this, it held a substantial $4.0 billion in cash and equivalents (www.sec.gov). Net debt was therefore only around $700 million – very modest for a firm with over $2 billion in annual operating profit. Cardinal maintains investment-grade credit ratings (with covenants triggering if ratings fall below BBB-/Baa3) (www.sec.gov). It has ample liquidity, including an undrawn $2.0 billion revolving credit facility and commercial paper program (www.sec.gov).

Debt maturities are well-staggered. Upcoming principal due in fiscal 2024 was $792 million, followed by $428 million in 2025 and $530 million in 2026 (www.sec.gov). The largest maturity is about $1.3 billion due in FY2027, after which only minimal amounts come due until ~$1.6 billion beyond 2028 (www.sec.gov). This runway gives management flexibility to refinance on favorable terms. Cardinal’s average interest rate on debt was about 5% as of mid-2023 (www.sec.gov). Annual interest expense was approximately $203 million in FY2023 (www.sec.gov), covered more than 10× by EBIT on a non-GAAP basis. Even including lease obligations and other fixed charges, coverage ratios are comfortable given EBITDA in the ~$3 billion range.

One sizeable liability to note is Cardinal’s opioid litigation settlement. The company has $5.87 billion accrued for opioid-related claims (www.sec.gov), to be paid out over ~18 years as part of a nationwide settlement. Cardinal made a $378 million payment in July 2023 as its third annual installment (www.sec.gov). These payments (roughly $400 million per year initially) act like a debt-like cash outflow, but are already reserved on the balance sheet. Crucially, the opioid settlement removed a major legal uncertainty for Cardinal. With the liability quantified and spread over many years, it remains very manageable – about 10% of yearly operating cash flow. Barring unforeseen litigation, Cardinal’s leverage outlook is quite healthy. Low net debt and strong cash generation give it capacity to invest or return capital, even as it meets settlement obligations and upcoming bond maturities.

Valuation and Comparative Metrics

Cardinal Health’s stock has been on a tear, reflecting its improving fundamentals. Shares climbed from under $50 in mid-2021 to all-time highs around $212 by early 2026 (www.macrotrends.net). In 2025 alone, CAH stock nearly doubled (+76% annual return) as investors rewarded the company’s turnaround (www.macrotrends.net). After this rally, valuation multiples are no longer in deep-value territory – yet still reasonable relative to peers. At a ~$208 share price, Cardinal trades around 27× forward earnings (using FY2025 guidance) and about 0.23× sales. For context, management recently raised FY2025 non-GAAP EPS guidance to $7.55–$7.70 (newsroom.cardinalhealth.com), implying only low-single-digit growth from the record $7.53 achieved in FY2024 (newsroom.cardinalhealth.com) (newsroom.cardinalhealth.com). On that outlook, the forward P/E ~27 is higher than Cardinal’s historical average but in line with the current market re-rating of distributors. Larger rival McKesson, for example, trades around 23–25× earnings (www.macrotrends.net) (www.macrotrends.net) after a similar stock surge.

Despite the elevated earnings multiple, Cardinal’s free cash flow yield is attractive. With nearly $4 billion in annual free cash flow and a ~$50 billion market cap, the FCF yield is roughly 7–8%. This highlights the cash-generative nature of the business (helped by working-capital efficiencies and some inflation tailwinds). On an enterprise basis, EV/EBITDA is in the mid-teens, reflecting the company’s light net debt. Another angle: the dividend yield of ~1% is well below its 5-year average, signaling the market’s shift to valuing Cardinal more for growth and capital gains than income.

Valuing Cardinal also means considering its two segments. The Pharmaceutical distribution arm is a stable, low-margin cash cow, while the Medical segment (now dubbed “Global Medical Products & Distribution”) has been a drag until recently. If the Medical unit’s turnaround continues, it could warrant a higher multiple more akin to medtech or manufacturing peers. There is speculative sum-of-parts upside if Cardinal were ever to separate the faster-growing medical products business from the steadier distribution unit. For now, management seems committed to both under one roof – and the market is pricing Cardinal as a hybrid. Overall, after a ~4× stock run, much of the easy value has been unlocked. But given Cardinal’s improved execution, record earnings (newsroom.cardinalhealth.com), and still-essential industry role, the valuation appears fair rather than frothy. Long-term investors are paying a market multiple for a business with quasi-utility characteristics (steady demand, high barriers) plus a turnaround kicker in the Medical segment.

Key Risks and Red Flags

While Cardinal Health’s outlook is stable, investors should weigh several risk factors and potential red flags:

– Customer Concentration: Cardinal depends on a few giant customers for a large portion of revenue. In fiscal 2023, its two biggest clients – CVS Health and OptumRx (UnitedHealth’s pharmacy arm) – accounted for roughly 25% and 16% of revenue, respectively (www.sec.gov). The top five customers together contributed over 50% of sales (www.sec.gov). Losing or repricing a major contract could materially impact Cardinal’s volume and profit. These large customers also wield strong bargaining power in pricing and payment terms. Cardinal’s long-term generics sourcing JV with CVS (Red Oak Sourcing) helps align interests (www.sec.gov), but the heavy concentration remains an ongoing risk.

– Thin Margins & Generic Pricing: Pharmaceutical distribution runs on razor-thin margins (typically 1–2% operating margins). Cardinal’s Pharmaceutical segment profitability can be sensitive to industry-wide generic drug price trends. Periods of generic price deflation or slowing brand inflation have hurt distributors in the past. Generic pricing pressure or unfavorable drugmaker pricing could squeeze segment profit margins, and Cardinal has limited ability to offset such external shifts (www.sec.gov). Additionally, any operational hiccups – inventory write-downs, shooting up of interest rates (raising carrying costs), or freight expense spikes – can quickly erode earnings when margins are slim.

– Medical Segment Execution: The Medical segment has been Cardinal’s problem child. Management’s improvement plan has shown progress (segment profit is climbing again), but execution risk remains. This segment faces competition from both manufacturers and other distributors (like privately-held Medline) (www.sec.gov). Cardinal had notable missteps here historically – e.g. a costly recall of surgical gowns in 2019 and struggles with the Cordis medical device business. In fact, Cardinal took a $1.2 billion goodwill impairment charge in FY2023 related to underperformance in the Medical unit (newsroom.cardinalhealth.com). Such write-downs are red flags, indicating that past acquisitions or strategies (like the $1.5 billion Cordis purchase) failed to deliver as expected. If the Medical segment’s turnaround stalls or if quality issues (product recalls, FDA compliance problems) resurface, it could once again drag on overall earnings. Investors will want to see consistent improvement in margins and reliable execution in this unit, given its slimmer margin for error.

– Legal and Regulatory Overhang: Although the nationwide opioid settlement is largely resolved, Cardinal remains under scrutiny. Under the settlement, distributors (including Cardinal) agreed to enhanced compliance measures and monitoring of controlled substance orders (www.sec.gov). Any future failure in compliance could bring fines or renewed litigation. Outside of opioids, Cardinal faces some ongoing product liability suits (e.g. related to legacy IVC filters from the Cordis business) (www.sec.gov). There’s also regulatory risk from potential healthcare reforms – for instance, changes to drug reimbursement (Medicare/340B program reforms) or distributor licensing rules. While Cardinal has navigated these issues so far, the heavily-regulated nature of drug distribution means unforeseen regulatory changes could pose a risk. Cybersecurity is another emerging concern, as Cardinal manages sensitive data across thousands of customers and suppliers (www.sec.gov). Any major systems failure or breach could disrupt operations.

– Macroeconomic and Market Risks: Healthcare demand is relatively defensive, but Cardinal isn’t immune to macro factors. Inflation affects its costs (labor, fuel) and interest rates affect its net interest income/expense. Notably, higher interest rates have actually benefitted distributors’ bottom lines recently by boosting interest earned on pharma customer receivables and inventory financing. However, if the economy enters recession, hospital budget tightening or pharmacy bankruptcies (customer credit risk) could create headwinds (www.sec.gov) (www.sec.gov). Another market risk: valuation risk. After the stock’s huge run-up, investor expectations are higher. Any earnings miss or guidance cut (even for reasons outside Cardinal’s control) could spur a sharp stock pullback. The current low dividend yield also offers little cushion if shares correct. New investors thus face the risk of multiple compression if sentiment reverses or growth disappoints.

In sum, Cardinal Health’s risks are largely those inherent to a large-scale distributor with a troubled past segment – customer concentration, wafer-thin margins, execution slip-ups, and external regulation. The company’s recent actions have mitigated some of these issues (for example, settling opioid claims and restructuring the medical division), but they remain areas to monitor closely.

Open Questions and Outlook

Looking ahead, several key questions remain open for Cardinal Health’s stakeholders:

– Will the sum-of-parts value be unlocked? Now that the Medical segment (Global Medical Products & Distribution) is recovering, will Cardinal consider a spinoff or sale down the road? The 2022 shareholder cooperation agreement indicates openness to portfolio changes (www.prnewswire.com) (www.prnewswire.com). A separation isn’t imminent, but investors wonder if a focused medical products company could command a higher valuation multiple, while the core drug distribution business could shine on its own. Management has thus far emphasized fixing, not selling, the Medical unit – but this strategic question persists.

– Can Cardinal sustain its earnings growth? FY2024 saw non-GAAP EPS jump ~29% to $7.53 (newsroom.cardinalhealth.com), aided by cost cuts, buybacks, and a rebound in Medical margins. However, FY2025 guidance calls for only modest growth (newsroom.cardinalhealth.com). With many efficiency gains realized, Cardinal must find new growth drivers to move the needle. One potential driver is the Specialty Pharmaceuticals arena – high-cost, complex drugs (like oncology and biologics) that distributors handle for clinics and health systems. Cardinal’s renaming of its main unit to “Pharmaceutical & Specialty Solutions” hints at emphasis here (newsroom.cardinalhealth.com). How successfully it expands in specialty distribution and services (data analytics, patient solutions) will influence its growth trajectory. Additionally, international growth (Cardinal has a presence in China and other markets) could contribute, though it’s a smaller piece.

– What will capital allocation look like at record prices? With leverage low and cash flows high, Cardinal has flexibility. Thus far excess cash went to buy back undervalued shares. Now that CAH stock trades above $200, will management taper repurchases? Future cash might be directed to debt reduction (ahead of the FY2027 maturity bulge) or selective M&A. Any acquisition would likely focus on bolstering higher-margin areas (e.g. specialty distribution, medical products, or healthcare tech) rather than expanding core drug wholesaling. Investors will be watching whether Cardinal continues its aggressive buyback tempo or rebalances its capital deployment given the stock’s revaluation.

– Is the stock still a buy at all-time highs? This is perhaps the central question for investors. The fundamentals are strong: improving operations, secure dividend, and fortress balance sheet. Yet the stock’s multiple now embeds a lot of optimism. Bulls could argue Cardinal deserves a premium given its resilience and improving mix, and point to peaking interest rates that could boost its net interest earnings. Bears might counter that much of the turnaround is priced in, and any stumble in execution or margins could send the P/E back down. The answer likely hinges on your time horizon. Long-term, Cardinal’s indispensable role in healthcare distribution and revamped management ethos (with Elliott keeping watch) provide confidence. In the near-term, however, new investors may prefer to wait for dips or a clearer margin of safety before accumulating shares.

Conclusion

Crinetics’ launch of a CAH trial might be grabbing headlines, but the ticker CAH – Cardinal Health – presents its own compelling narrative. After years of underperformance, Cardinal has emerged as a leaner, more focused enterprise delivering record profits (newsroom.cardinalhealth.com). It offers a rare combination of attributes: a decades-long dividend track record (www.dividend.com), rock-solid cash flows, and a dominant position in an essential industry. The company has addressed legacy issues (settling opioid litigation and writing down bad acquisitions) and is reaping the rewards of an activist-instilled urgency in execution (www.prnewswire.com).

At the same time, investors must balance those strengths against a stock that has rerated to a higher valuation and remaining risks around customer concentration and execution. Cardinal Health today is far from a “cigar butt” deep value play – it’s a stable, cash-rich business priced for measured growth. For investors seeking a cornerstone healthcare holding, Cardinal offers quality and reliability, albeit with a modest income yield. “Don’t miss this opportunity” doesn’t mean chase the stock blindly, but rather don’t overlook this transformed blue-chip. A methodical due diligence (as in this report) shows a company with more green flags than red, and one that could continue rewarding shareholders over the long haul. In sum, Cardinal Health has launched into a new trial of its own – proving that even a mature distributor can reinvent itself. Thus far, the results are promising, making CAH a stock worth watching for the next phase of opportunity.

Sources: Cardinal Health SEC filings and earnings releases; company investor relations data; Dividend.com; CNBC analysis; Investing.com news (za.investing.com) (www.cnbc.com) (www.dividend.com) (www.sec.gov) (www.sec.gov) (www.sec.gov) (newsroom.cardinalhealth.com) (www.prnewswire.com) (newsroom.cardinalhealth.com).

For informational purposes only; not investment advice.